Enter generative AI, which the pharma industry is adopting at a terrific rate. By ingesting and analysing vast biological ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.

The Singapore-based AI clinical trial engine powering Asia’s—especially China’s—rapid rise in the biotech industry. Deep ...

On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his ...

From the corporate jets of Teterboro Airport to the crowded halls of the J.P. Morgan Healthcare Conference, it’s a good time ...

Next week, drugmakers will arrive at the JPMorgan Healthcare Conference in San Francisco feeling far more confident than in ...

While the Trump administration remains unpredictable, some pharma experts are optimistic that the regulatory landscape will ...

The newly committed suite is the first of four manufacturing suites ProMed is constructing at Niagara Lane to support growing demand for manufacture of ophthalmic implants and other sustained-release ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, ...

The June agreement (PDF) established a fixed revenue-sharing model, with TME Pharma receiving a “larger share of future ...

Vicks accrued a total of 4.3 billion impressions on an estimated national TV ad spend of $18.9 million. The top network for ...